Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
AAPG Catalyst Timeline
Dated clinical, regulatory and corporate events for Ascentage Pharma Group International - American Depository Shares
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ascentage Pharma Group International - American Depository Shares
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How AAPG actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-13 | Lisaftoclax (APG-2575) | Phase 2 data readout | Phase 2 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lisaftoclax Small MoleculesNCT04215809 | CLL/SLL | Phase 3 | RECRUITING | 888 | Jun 30, 2027 | ||||||
| Lisaftoclax Small MoleculesNCT06641414 | Higher-risk Myelodysplastic Syndrome | Phase 3 | RECRUITING | 490 | Dec 1, 2029 | ||||||
| APG-2575 Small MoleculesNCT06389292 | Acute Myeloid Leukemia | Phase 3 | RECRUITING | 486 | Mar 26, 2029 | ||||||
| APG-2575 Small MoleculesNCT06182969 | SLE | Phase 1/2 | RECRUITING | 40 | Dec 1, 2026 | ||||||
| Lisaftoclax Small MoleculesNCT04501120 | Relapsed/Refractory Acute Myeloid Leukaemia | Phase 1/2 | RECRUITING | 682 | Sep 1, 2029 | ||||||
| APG-2575 Small MoleculesNCT03913949 | Chronic Lymphocytic Leukemia | Phase 2 | ACTIVE NOT_RECRUITING | 272 | Dec 31, 2026 | ||||||
| Olverembatinib Small MoleculesNCT04260022 | Chronic Myeloid Leukemia | Phase 3 | RECRUITING | 575 | Mar 31, 2030 | ||||||
| Olverembatinib Small MoleculesNCT06051409 | Ph+ ALL | Phase 3 | RECRUITING | 350 | Jun 30, 2029 | ||||||
| Olverembatinib Small MoleculesNCT06640361 | GIST | Phase 3 | RECRUITING | 40 | Jun 30, 2029 | ||||||
| HQP1351 Small MoleculesNCT03594422 | Gastrointestinal Stromal Tumor (GIST) | Phase 1 | RECRUITING | 100 | Dec 1, 2028 | ||||||
| APG-115 Small MoleculesNCT04785196 | Liposarcoma | Phase 1/2 | RECRUITING | 95 | Jan 1, 2027 | ||||||
| APG-115 Small MoleculesNCT03611868 | Unresectable or Metastatic Melanoma or Advanced Solid Tumors | Phase 1/2 | ACTIVE NOT_RECRUITING | 230 | Dec 30, 2025 | ||||||
| APG-115 Small MoleculesNCT05701306 | Neuroblastoma | Phase 1/2 | RECRUITING | 100 | Dec 31, 2027 | ||||||
| APG-115 Small MoleculesNCT04496349 | T-Prolymphocytic Leukemia | Phase 2 | RECRUITING | 78 | May 31, 2027 | ||||||
| APG-5918 Small MoleculesNCT05773586 | Anemia | Phase 1 | RECRUITING | 105 | Jul 15, 2028 | ||||||
| APG-2449 Small MoleculesNCT03917043 | Advanced Solid Cancer | Phase 1 | RECRUITING | 165 | Jan 1, 2028 | ||||||
| APG-2449 Small MoleculesNCT06687070 | Platinum-resistant Recurrent Ovarian Cancer | Phase 1 | RECRUITING | 90 | May 1, 2028 | ||||||
| APG-3288 Small MoleculesNCT07424833 | Relapsed/Refractory Hematological Malignancies | Phase 1 | RECRUITING | 180 | Dec 1, 2031 | ||||||
| APG-2575 Small MoleculesCompletedNCT04260217 | Waldenstrom Macroglobulinemia | Phase 1 | COMPLETED | 46 | Aug 13, 2025 | ||||||
| HQP1351 Small MoleculesCompletedNCT03882281 | Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | COMPLETED | 156 | Nov 16, 2019 | ||||||
| HQP1351 Small MoleculesCompletedNCT04126707 | Chronic Myeloid Leukemia (CML) | Phase 1 | COMPLETED | 6 | Jan 13, 2020 | ||||||
| APG-115 Small MoleculesCompletedNCT02935907 | Patients With Advanced Solid Tumor or Lymphoma | Phase 1 | COMPLETED | 50 | Jun 28, 2019 | ||||||
| APG-1252 Small MoleculesCompletedNCT04001777 | EGFR Positive Non-small Cell Lung Cancer | Phase 1 | COMPLETED | 73 | May 27, 2025 | ||||||
| APG-1252 Small MoleculesCompletedNCT03080311 | Small Cell Lung Cancer | Phase 1 | COMPLETED | 50 | Jul 17, 2020 | ||||||
| APG-1387 Small MoleculesCompletedNCT03386526 | Advanced Solid Tumors or Hematologic Malignancies | Phase 1 | COMPLETED | 90 | Nov 30, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every AAPG program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| olverembatinib | chronic myeloid leukemia | Phase 3 | 2026-06-14 | deep and durable responses in patients with chronic-phase CML (CML-CP) without the T315I mutationRead More | Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 CongressRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Zhai YifanOfficer (Chief Medical Officer) | Option | 95,575 1,193,569 held | $0.00 | 05/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AAPG
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in AAPG for Q3 2026. | ||||
Ownership Trends
AAPG Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How AAPG ranks across every disease it competes in
AAPG News
Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib
Ascentage Pharma announced that its drugs, lisaftoclax and olverembatinib, are included in China's 2026 National Reimbursement Drug List. Lisaftoclax is now available for CLL/SLL patients, while olverembatinib's coverage has been renewed for CML patients. This development enhances patient access to these innovative therapies, effective from January 1, 2027.
Read more →Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026
Ascentage Pharma announced that multiple studies, including APG-5918, will be presented at the ASH 2026 Annual Meeting. APG-5918, an EED inhibitor, shows promising efficacy in treating relapsed/refractory T-cell lymphoma. Additionally, data on combination therapies of olverembatinib and lisaftoclax demonstrate high response rates in various hematologic malignancies.
Read more →Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London
Ascentage Pharma announced its participation in two investor conferences in London on November 16 and 17, 2026. The events will include company presentations and one-on-one meetings with investors. Ascentage is recognized for its innovative therapies, including Olverembatinib and Lisaftoclax, which target unmet medical needs in cancer.
Read more →Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
Ascentage Pharma's lisaftoclax has been granted Breakthrough Therapy Designation in China for treatment-naïve CLL/SLL patients. This designation allows for expedited development and review, addressing significant clinical needs. The drug, in combination with acalabrutinib, aims to improve treatment outcomes for patients with limited options after standard therapies.
Read more →Ascentage Pharma to Participate in Four Upcoming Investor Conferences
Ascentage Pharma Group International will participate in four upcoming investor conferences in New York, showcasing its innovative therapies and recent product approvals. The conferences include presentations and one-on-one meetings, allowing investors to engage with the company's management. Ascentage continues to develop therapies targeting unmet medical needs in cancer, bolstered by a strong pipeline and strategic partnerships.
Read more →Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
Ascentage Pharma reported first-half 2026 revenue of US$44.5 million, a 29 percent increase from the prior year period. The company also announced the appointments of Dr. Faical Miyara and Mr. James Ziegler to its executive leadership team. Nine registrational Phase III clinical trials are currently in progress worldwide. These updates accompany the release of the company's interim unaudited financial results.
Read more →Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
Ascentage Pharma will participate in the Evercore 2nd Annual China Biotech Summit from August 17-19, 2026. The company's management will engage in a fireside chat and one-on-one investor meetings during the event. Ascentage Pharma is recognized for its innovative therapies targeting cancer, including its approved products and ongoing clinical trials.
Read more →Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
Ascentage Pharma Group International will announce its six-month interim results for 2026 on August 19, 2026. The company will host investor webcasts in both Mandarin and English to discuss these results and provide business updates. Ascentage Pharma is recognized for its innovative cancer therapies and has multiple ongoing Phase III trials.
Read more →Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
Ascentage Pharma has appointed Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer. These appointments aim to enhance the company's global business development and commercialization efforts, particularly in the oncology sector. Both executives bring extensive experience in their respective fields, which aligns with Ascentage's strategy to expand its global footprint and advance its innovative therapies.
Read more →Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
Ascentage Pharma's Chairman and CEO, Dr. Dajun Yang, has been named No. 3 in The Medicine Maker Power List 2026 for his contributions to oncology and drug development. The recognition highlights his leadership in advancing innovative cancer therapies, including olverembatinib and lisaftoclax. Ascentage Pharma continues to progress with multiple global Phase III trials, addressing significant unmet medical needs in cancer treatment.
Read more →Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
Ascentage Pharma presented 17 clinical updates at the EHA2026 Congress, showcasing the efficacy of olverembatinib and lisaftoclax in treating hematologic malignancies. Olverembatinib demonstrated significant responses in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Lisaftoclax showed promising results in pediatric patients with relapsed/refractory conditions. These findings support the ongoing development of these therapies.
Read more →VOLUNTARY ANNOUNCEMENT PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME
Ascentage Pharma Group International announced a voluntary share purchase by the Trustee for the 2022 RSU Scheme. On June 11, 2026, the Trustee acquired 110,000 existing shares for a total consideration of HK$3,671,094, representing approximately 0.0294% of the total issued shares. This purchase aims to fulfill the company's obligations related to the RSUs upon their vesting. No new grants have been made under the RSU Scheme aside from initial awards since June 2022, indicating a steady approach to equity compensation.
Read more →Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
Ascentage Pharma presented updated clinical data for olverembatinib as a second-line therapy for chronic-phase chronic myeloid leukemia (CML-CP) at the 2026 ASCO Annual Meeting. The study reported a complete cytogenetic response rate of 91.3% and a major molecular response rate of 60.9% after 24 cycles of treatment. The drug demonstrated a manageable safety profile, with no new safety signals identified, reinforcing its potential in treating patients who failed first-line therapy.
Read more →Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
Ascentage Pharma presented its first dataset on alrizomadlin (APG-115), an MDM2-p53 inhibitor, at the 2026 ASCO Annual Meeting. The data showed promising antitumor activity in pediatric patients with relapsed/metastatic rhabdomyosarcoma and other soft-tissue sarcomas. Alrizomadlin demonstrated a favorable safety profile and was included in China's SPARK Plan for further development in pediatric oncology.
Read more →Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
Ascentage Pharma presented promising data on olverembatinib combined with blinatumomab at the 2026 ASCO Annual Meeting. The Phase Ib study showed high response rates in patients with relapsed/refractory Ph+ BCP-ALL and CML-LBP. The combination therapy was well tolerated, indicating its potential as a novel treatment strategy for these challenging hematologic malignancies.
Read more →ASCENTAGE PHARMA GROUP INTERNATIONAL
Ascentage Pharma Group International made a voluntary announcement regarding the 2022 RSU Scheme. This announcement details the purchase of 50,000 existing shares by the Trustee on-market for the purpose of satisfying RSUs at vesting. As of May 28, 2026, the total number of purchased shares under the scheme amounts to 2,315,000 shares. The Trustee will hold these shares in accordance with the rules of the RSU Scheme and will not exercise voting rights attached to them.
Read more →Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
Ascentage Pharma announced the presentation of six abstracts at the 2026 ASCO Annual Meeting, showcasing data from ongoing studies of its lead drug candidates. Notably, olverembatinib demonstrated high response rates in patients with chronic myeloid leukemia and other hematological malignancies. The meeting will occur from May 29 to June 2, 2026, in Chicago, IL.
Read more →POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 20, 2026
Ascentage Pharma Group International held its annual general meeting on May 20, 2026, where all proposed resolutions were approved. A total of 373,348,863 shares were entitled to vote, with significant support for financial statements and director re-elections. Notably, resolutions related to granting RSUs and Options to key executives were also approved, although the executives abstained from voting. The company aims to continue its operational growth and leadership structure as indicated by the positive AGM results.
Read more →Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress
Ascentage Pharma announced that it will present 17 clinical advances at the upcoming EHA2026 Congress in Stockholm, Sweden. The presentations will include key data on Olverembatinib and Lisaftoclax, two innovative therapies for hematologic malignancies. This event is a major platform for sharing research advancements in hematology.
Read more →